HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BAO PHARMA-B

16.280

+0.4602.91%

Volume:246.10K

Turnover:3.98M

Market Cap:5.27B

PE:-10.27

High:16.400

Open:15.850

Low:15.380

Close:15.820

52wk High:206.000

52wk Low:15.300

Shares:324.00M

HK Float Shares:153.00M

Volume Ratio:6.53

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.586

ROE:-31.30%

ROA:-10.95%

PB:3.12

PE(LYR):-10.27

PS:265.45

Loading ...

Overview Company News Filings

Shanghai Bao Pharmaceuticals Says NMPA Approves IND Application for BJ044 Injection

BAO PHARMA-B Surges Over 10% In Session Following Clinical Trial Approval for Recombinant Ulinastatin

Bao Pharma repurchases 95,200 H shares for HKD 1.69 million; outstanding share count falls 0.06%

Bulletin Express

BAO PHARMA-B (02659) Repurchases 95,200 Shares for Approximately HK$1.686 Million on June 30

Shanghai Bao Pharma Files HKEX Next-day Disclosure on Share Buyback at HKD 17.38-17.81

Shanghai Bao Pharmaceuticals Says NMPA Approves IND Application for BJ044 Injection

Yidu Tech Achieves Historic Annual Profit Turnaround; Key HKEX Announcements on M&A, Clinical Trials, and AI Partnerships

BAO PHARMA-B's Investigational New Drug Application for BJ044 (Recombinant Ulinastatin) Receives NMPA Approval

Shanghai Bao Pharmaceuticals Co - Nmpa Approves Ind Application for Bj044 Injection, Permitting Clinical Trials

THOMSON REUTERS

BAO PHARMA-B Shares Surge in Morning Session Following NMPA Acceptance of New Drug Application

Bubble Burst Leaves Stock in Tatters: This Company's Shares Suffer a 'Foot-Ankle Chop'

BAO PHARMA-B Surges Over 4% on Successful Phase II Trial for Novel IgG Degrading Enzyme

Bao Pharma Secures U.S. FDA IND Clearance to Begin Clinical Trials of Subcutaneous Ceftriaxone Candidate BJ007

Bulletin Express

BAO PHARMA-B Receives FDA Clearance for Clinical Trial of Subcutaneous Antibiotic Candidate BJ007

Shanghai Bao Pharma says US FDA clears IND for BJ007 subcutaneous infusion trial

Shanghai Bao Pharmaceuticals Co - U.S. FDA Approves Ind for Subcutaneous Infusion of Bj007 for Injection on May 27, 2026

THOMSON REUTERS

Movement Alert｜Bao Pharmaceuticals-B Falls 5.19% in Regular Trading, Continued Low-Level Consolidation After Flash Crash Compounded by Biotech Sector Weakness

BAO PHARMA-B's Groundbreaking Low-Immunogenic IgG Degrading Enzyme Ricefidase Reports Positive Phase II Results for Anti-GBM Disease

Movement Alert｜Bao Pharmaceuticals-B Rises 5.59% in Regular Trading, Core Pipeline KJ103 NDA Accepted by NMPA with Priority Review

Bao Pharmaceuticals' Application for Desensitization Therapy Drug Accepted in China

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/02659/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"BAO PHARMA-B","latestPrice":16.28,"timestamp":1788143512411,"preClose":15.82,"halted":0,"volume":246100,"delay":0,"changeRate":0.029077117572692848,"floatShares":153000000,"shares":324000000,"eps":-1.5857266277292148,"marketStatus":"Trading","change":0.46,"latestTime":"08-31 10:32:07","open":15.85,"high":16.4,"low":15.38,"amount":3978362,"amplitude":0.064475,"askPrice":16.28,"askSize":400,"bidPrice":16.2,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.3731483135274978,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1788148800000},"marketStatusCode":2,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":15.82,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":6.533019,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":153000000,"roa":"-10.95%","roe":"-31.30%","lyrEps":-1.58583,"volumeRatio":6.533019,"shares":324000000,"dividePrice":0,"high":16.4,"amplitude":0.064475,"preClose":15.82,"low":15.38,"week52Low":15.3,"pbRate":"3.12","psRate":"265.45","week52High":206,"institutionHeld":0,"latestPrice":16.28,"committee":-0.333333,"eps":-1.5858297075033123,"divideRate":0,"volume":246100,"delay":0,"ttmEps":-1.373237574699938,"open":15.85,"prevYearClose":77.55,"prevWeekClose":15.82,"prevMonthClose":17.25,"prevQuarterClose":18,"fiveDayClose":15.73,"twentyDayClose":17.13,"sixtyDayClose":22.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1779984000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-08-28","current":-11.724854,"percent":0.994253,"low":-150.791275,"twenty":-75.047246,"median":-53.651638,"eighty":-12.841314,"high":-11.128507,"avg":-47.396445,"sd":35.818109,"marketCap":5157026776},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-27","current":-65.400661,"twenty":-104.714701,"median":-74.674242,"eighty":-58.326024,"marketCap":29273135557},{"date":"2026-04-02","current":-74.510382,"twenty":-96.653813,"median":-73.605533,"eighty":-59.04256,"marketCap":33510894602},{"date":"2026-04-10","current":-71.602503,"twenty":-91.308972,"median":-74.057958,"eighty":-59.568794,"marketCap":32451454840},{"date":"2026-04-17","current":-64.454748,"twenty":-86.399914,"median":-73.087213,"eighty":-60.479603,"marketCap":29224238337},{"date":"2026-04-24","current":-55.967849,"twenty":-84.718643,"median":-71.1642,"eighty":-60.173931,"marketCap":25377657050},{"date":"2026-04-30","current":-18.543355,"twenty":-83.426575,"median":-70.300184,"eighty":-58.506399,"marketCap":8410321797},{"date":"2026-05-08","current":-19.625214,"twenty":-81.092081,"median":-69.74185,"eighty":-56.760202,"marketCap":8931892141},{"date":"2026-05-15","current":-17.930681,"twenty":-79.944236,"median":-68.961959,"eighty":-55.831299,"marketCap":8182134771},{"date":"2026-05-22","current":-17.55647,"twenty":-79.579829,"median":-66.237091,"eighty":-53.674239,"marketCap":7993065521},{"date":"2026-05-29","current":-17.509903,"twenty":-78.962132,"median":-66.085797,"eighty":-51.516739,"marketCap":7999585151},{"date":"2026-06-05","current":-15.389804,"twenty":-78.220574,"median":-65.202887,"eighty":-19.743808,"marketCap":7041199644},{"date":"2026-06-12","current":-13.774642,"twenty":-77.936107,"median":-64.592987,"eighty":-19.178821,"marketCap":6297961903},{"date":"2026-06-18","current":-12.785133,"twenty":-77.726882,"median":-64.454748,"eighty":-18.7468,"marketCap":5857886926},{"date":"2026-06-26","current":-11.736313,"twenty":-77.358698,"median":-62.675612,"eighty":-18.25553,"marketCap":5352615655},{"date":"2026-07-03","current":-13.348826,"twenty":-77.285436,"median":-61.290684,"eighty":-17.828553,"marketCap":6092593580},{"date":"2026-07-10","current":-14.187594,"twenty":-77.122448,"median":-60.663453,"eighty":-17.509903,"marketCap":6467472265},{"date":"2026-07-17","current":-12.348746,"twenty":-76.777398,"median":-59.36056,"eighty":-15.389804,"marketCap":5649258788},{"date":"2026-07-24","current":-12.28898,"twenty":-76.640212,"median":-57.965274,"eighty":-14.102609,"marketCap":5623180271},{"date":"2026-07-31","current":-12.265678,"twenty":-76.228711,"median":-57.553252,"eighty":-13.925373,"marketCap":5623180271},{"date":"2026-08-07","current":-12.759971,"twenty":-76.015489,"median":-56.434485,"eighty":-13.758151,"marketCap":5861146740},{"date":"2026-08-14","current":-11.978357,"twenty":-75.491436,"median":-55.967849,"eighty":-13.50755,"marketCap":5509086758},{"date":"2026-08-21","current":-11.379099,"twenty":-75.31975,"median":-54.455852,"eighty":-13.139203,"marketCap":5245041771},{"date":"2026-08-28","current":-11.185615,"twenty":-75.047246,"median":-53.651638,"eighty":-12.841314,"marketCap":5157026776}],"updateTime":1788142198659},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649964964","title":"Shanghai Bao Pharmaceuticals Says NMPA Approves IND Application for BJ044 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2649964964","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649964964?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:15","pubTimestamp":1783322126,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Shanghai Bao Pharmaceuticals Co Ltd <2659.HK>::*NMPA APPROVES IND APPLICATION FOR BJ044 INJECTION, PERMITTING CLINICAL TRIALS*Further company coverage: 2659.HK* ((Reuters.Briefs@th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSD8BSg84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166966432","title":"BAO PHARMA-B Surges Over 10% In Session Following Clinical Trial Approval for Recombinant Ulinastatin","url":"https://stock-news.laohu8.com/highlight/detail?id=1166966432","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166966432?lang=en_us&edition=fundamental","pubTime":"2026-07-03 10:02","pubTimestamp":1783044169,"startTime":"0","endTime":"0","summary":"Shares of BAO PHARMA-B (02659) climbed more than 10% during the trading session. At the time of writing, the stock is up 4.82%, trading at HK$18.92 with a turnover of HK$8.4168 million. The company...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119988416","title":"Bao Pharma repurchases 95,200 H shares for HKD 1.69 million; outstanding share count falls 0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119988416","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119988416?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:04","pubTimestamp":1782817473,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed that it bought back 95,200 H shares on 30 June 2026 through the Hong Kong Stock Exchange. The shares were repurchased at prices between...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153676444","title":"BAO PHARMA-B (02659) Repurchases 95,200 Shares for Approximately HK$1.686 Million on June 30","url":"https://stock-news.laohu8.com/highlight/detail?id=1153676444","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153676444?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:54","pubTimestamp":1782816873,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) has announced that on June 30, 2026, the company repurchased 95,200 of its own shares at a total cost of approximately HK$1.686 million.The share buyback was executed at prices ranging from HK$17.38 to HK$17.81 per share.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647537020","title":"Shanghai Bao Pharma Files HKEX Next-day Disclosure on Share Buyback at HKD 17.38-17.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2647537020","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647537020?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:50","pubTimestamp":1782816637,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharma files HKEX next-day disclosure on share buyback at HKD 17.38-17.81Shanghai Bao Pharmaceuticals repurchased 95,200 H shares on June 30, 2026 for treasury, with no shares cancelled.B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL4hrxhR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647728585","title":"Shanghai Bao Pharmaceuticals Says NMPA Approves IND Application for BJ044 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2647728585","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647728585?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:40","pubTimestamp":1782783652,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Shanghai Bao Pharmaceuticals Co Ltd <2659.HK>::*NMPA APPROVES IND APPLICATION FOR BJ044 INJECTION, PERMITTING CLINICAL TRIALS*Further company coverage: 2659.HK* ((Reuters.Briefs@th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nRSD8BSg84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173979252","title":"Yidu Tech Achieves Historic Annual Profit Turnaround; Key HKEX Announcements on M&A, Clinical Trials, and AI Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=1173979252","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173979252?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:10","pubTimestamp":1782781850,"startTime":"0","endTime":"0","summary":"Key corporate developments have been announced across the Hong Kong market. Bao Pharma-B (HKEX: 02659) reported that the clinical trial application for its BJ044 injection (recombinant ulinastatin)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","02158","BK1148","BK1189","BK1214","BK1617","VXUS","BK1149","BK1161","02431","BK1144","BK4588","00638","01783","BK1518","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102812606","title":"BAO PHARMA-B's Investigational New Drug Application for BJ044 (Recombinant Ulinastatin) Receives NMPA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1102812606","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102812606?lang=en_us&edition=fundamental","pubTime":"2026-06-30 08:32","pubTimestamp":1782779549,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (ASX: 02659) has announced that on June 29, 2026, the Investigational New Drug (IND) application for its self-developed, globally leading BJ044 injection (recombinant ulinastatin, BJ044)...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647300942","title":"Shanghai Bao Pharmaceuticals Co - Nmpa Approves Ind Application for Bj044 Injection, Permitting Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2647300942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647300942?lang=en_us&edition=fundamental","pubTime":"2026-06-30 06:36","pubTimestamp":1782772602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN43111G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197374184","title":"BAO PHARMA-B Shares Surge in Morning Session Following NMPA Acceptance of New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1197374184","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197374184?lang=en_us&edition=fundamental","pubTime":"2026-06-29 11:10","pubTimestamp":1782702635,"startTime":"0","endTime":"0","summary":"Shares of BAO PHARMA-B (ASX: 02659) rose sharply during the morning trading session. At the time of reporting, the stock was up 9.01% to HK$17.9, with a turnover of HK$19.52 million.The upward...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","IPOS","BK1161","02659","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150861943","title":"Bubble Burst Leaves Stock in Tatters: This Company's Shares Suffer a 'Foot-Ankle Chop'","url":"https://stock-news.laohu8.com/highlight/detail?id=1150861943","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150861943?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:17","pubTimestamp":1781615869,"startTime":"0","endTime":"0","summary":"Shares of BAO PHARMA-B (HKEX: 2659), which had just completed six months of listing on the Hong Kong Stock Exchange, fell another 4.21% today (16th), closing at HK$18.41 to set a new historical...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105703662","title":"BAO PHARMA-B Surges Over 4% on Successful Phase II Trial for Novel IgG Degrading Enzyme","url":"https://stock-news.laohu8.com/highlight/detail?id=1105703662","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105703662?lang=en_us&edition=fundamental","pubTime":"2026-06-11 10:06","pubTimestamp":1781143587,"startTime":"0","endTime":"0","summary":"Shares of BAO PHARMA-B (ASX: 02659) have surged more than 4%. At the time of writing, the stock is up 4.03% to HKD 19.88, with a turnover of HKD 7.918 million.The recent price movement follows the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK4585","VXUS","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127315645","title":"Bao Pharma Secures U.S. FDA IND Clearance to Begin Clinical Trials of Subcutaneous Ceftriaxone Candidate BJ007","url":"https://stock-news.laohu8.com/highlight/detail?id=1127315645","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127315645?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:45","pubTimestamp":1781088350,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (“Bao Pharma”) announced that the U.S. Food and Drug Administration granted Investigational New Drug (IND) clearance on 27 May 2026 for BJ007, a subcutaneous...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193425517","title":"BAO PHARMA-B Receives FDA Clearance for Clinical Trial of Subcutaneous Antibiotic Candidate BJ007","url":"https://stock-news.laohu8.com/highlight/detail?id=1193425517","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193425517?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:32","pubTimestamp":1781087562,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (ASX: 02659) has announced that its Investigational New Drug (IND) application for BJ007, a subcutaneous formulation of ceftriaxone sodium, has been approved by the U.S. Food and Drug...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LABU","02659","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440872","title":"Shanghai Bao Pharma says US FDA clears IND for BJ007 subcutaneous infusion trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440872","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642440872?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:27","pubTimestamp":1781087254,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals won US FDA clearance for an IND for subcutaneous infusion of BJ007, enabling the start of clinical trials.The study compares BJ007 subcutaneous infusion with IV ceftriaxone in healthy participants, focusing on pharmacokinetics and bioavailability.BJ007 is a subcutaneous ceftriaxone sodium candidate aimed at bacterial infections, targeting patients with difficult venous access.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL3HdRbQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440848","title":"Shanghai Bao Pharmaceuticals Co - U.S. FDA Approves Ind for Subcutaneous Infusion of Bj007 for Injection on May 27, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642440848?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:27","pubTimestamp":1781087248,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nFWN42I0EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175689548","title":"Movement Alert｜Bao Pharmaceuticals-B Falls 5.19% in Regular Trading, Continued Low-Level Consolidation After Flash Crash Compounded by Biotech Sector Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=1175689548","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175689548?lang=en_us&edition=fundamental","pubTime":"2026-06-08 11:55","pubTimestamp":1780890919,"startTime":"0","endTime":"0","summary":"On June 8, Bao Pharmaceuticals-B declined 5.19% in regular trading, trading at 20.42 HKD/share, with trading volume of 16.43 million HKD. The stock continues to consolidate at depressed levels...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170212748","title":"BAO PHARMA-B's Groundbreaking Low-Immunogenic IgG Degrading Enzyme Ricefidase Reports Positive Phase II Results for Anti-GBM Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=1170212748","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170212748?lang=en_us&edition=fundamental","pubTime":"2026-06-06 10:42","pubTimestamp":1780713753,"startTime":"0","endTime":"0","summary":"Significant results from a Phase II clinical study for a novel treatment in anti-GBM disease were presented at the 63rd European Renal Association Congress. The study, led by a team from Peking...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185904720","title":"Movement Alert｜Bao Pharmaceuticals-B Rises 5.59% in Regular Trading, Core Pipeline KJ103 NDA Accepted by NMPA with Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1185904720","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185904720?lang=en_us&edition=fundamental","pubTime":"2026-06-05 09:42","pubTimestamp":1780623753,"startTime":"0","endTime":"0","summary":"On June 5, Bao Pharmaceuticals-B rose 5.59% in regular trading, trading at 24.22 HKD/share, with trading volume of 20.86 million HKD.On the news front, the company announced on June 4 that the new...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640152754","title":"Bao Pharmaceuticals' Application for Desensitization Therapy Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2640152754","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640152754?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:03","pubTimestamp":1780574615,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals'  new drug application for KJ103 for injection was accepted by China's National Medical Products Administration and granted priority review status, according to a Thursday Hong Kong bourse filing.The acceptance is for use of the drug for desensitization therapy in highly sensitized kidney transplant patients.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":126,"code":"91000000","status":"200"}]}}